¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)
Prostate Cancer Biomarkers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
»óǰÄÚµå : 1797739
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 132 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,811,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,496,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,726,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº 2024³â 47¾ï ´Þ·¯·Î Æò°¡µÇ¾úÀ¸¸ç CAGR 13.5%·Î ¼ºÀåÇØ 2034³â±îÁö 165¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â °ÍÀº ƯÈ÷ ³²¼º Àα¸ÀÇ °í·ÉÈ­¿¡ ¼ö¹ÝÇÏ´Â Àü¸³¼±¾Ï ȯÀÚ ¼ö Áõ°¡¿Í °í±Þ Áø´Ü¹ýÀÇ ÁøÈ­ÀÔ´Ï´Ù. Á¶±â °ËÁø¿¡ ´ëÇÑ ÀǽÄÀÇ ³ô¾ÆÁü°ú Á¤ºÎ°¡ ÈÄ¿øÇÏ´Â Çコ Äɾî ÇÁ·Î±×·¥ Áõ°¡°¡ ÇÁ¶óÀ̸Ӹ® ÄɾîÀÇ ÇöÀå¿¡¼­ÀÇ Ã¤¿ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ÀΰøÁö´É ÁÖµµÀÇ Æò°¡, ¾×ü»ý°Ë, À¯Àüü ÇØ¼® Ç÷§Æû µî Â÷¼¼´ë Áø´ÜÀÇ ÅëÇÕÀ¸·Î Á¶±â ¹ß°ßÀÌ °­È­µÊ°ú µ¿½Ã¿¡ ¸ÂÃã Ä¡·á ¹æÄ§ÀÇ °áÁ¤ÀÌ Áö¿øµÇ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ½ÅÈï±¹¿¡¼­´Â ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç Á¤¹Ð ±â¹Ý °Ë»ç¹ý¿¡ ´ëÇÑ Á¢±ÙÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ÁÖµµ Àü·«Àº Á¤¹Ðµµ Çâ»ó, ħ½À¼º Àú°¨, Áø´Ü ¿öÅ©Ç÷οìÀÇ ½Å¼ÓÈ­¿¡ ÀÇÇØ ¾Ï ÀǷḦ À籸¼ºÇϰí ÀÖ½À´Ï´Ù.

Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ Market-IMG1

OPKO Health, Beckman Coulter, Bio-Rad Laboratories ¹× Bio-Techne°ú °°Àº ÁÖ¿ä ¾÷°è °øÇå ±â¾÷Àº Àü¸³¼± ¾Ï ¹ÙÀÌ¿À ¸¶Ä¿ ½ÃÀåÀÇ Çõ½ÅÀ» ÃßÁøÇÏ´Â ÃÖÀü¼±¿¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº ÃÖ÷´Ü Áø´Ü Ç÷§ÆûÀ» ÅëÇØ °¨ÁöÀÇ Á¤È®¼º°ú ¼Óµµ¸¦ ³ôÀÏ »Ó¸¸ ¾Æ´Ï¶ó °³º°È­µÈ ¾Ï Ä¡·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ºñħ½ÀÀûÀÌ°í ¹Î°¨ÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®À» °³¹ßÇϰí AI ±â¹Ý Áø´Ü ½Ã½ºÅÛ°ú ÅëÇÕÇÔÀ¸·Î½á Áúº´ÀÇ Á¶±â ¹ß°ß, ´õ ³ªÀº ÁøÇà ¸ð´ÏÅ͸µ ¹× º¸´Ù È¿°úÀûÀÎ Ä¡·á °èȹÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 47¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 165¾ï ´Þ·¯
CAGR 13.5%

´Ü¹éÁú ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¾ß´Â 2024³â 24¾ï ´Þ·¯¸¦ âÃâÇØ, CAGR 13.1%·Î ¼ºÀåÇϸ鼭 2034³â±îÁö 82¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À ¸¶Ä¿ÀÇ ÀÌÁ¡Àº ÀÓ»ó ÀûÀ¸·Î ³Î¸® ¹Þ¾Æ µé¿©Áö°í Áúº´ °ËÃâ ¹× ÁøÇà ÃßÀû¿¡ ÀÏ»óÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ Ä«Å×°í¸®ÀÇ ¹ÙÀÌ¿À¸¶Ä¿´Â Ç¥ÁØ Ç÷¾× ºÐ¼®À¸·Î ½±°Ô ÃøÁ¤ÇÒ ¼ö ÀÖÀ¸¸ç, ½Å·Ú¼º, ºñ¿ë È¿°ú, Àü¸³¼±¾Ï À§Çè°ú °­ÇÑ »ó°ü¼ºÀÌ ÀÔÁõµÇ¾ú±â ¶§¹®¿¡ ¿©ÀüÈ÷ ù ¹øÂ° Áø´Ü µµ±¸ÀÔ´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ Á¶»ç¸¦ ÅëÇØ ÀÌ·¯ÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ±â¼úÀº °è¼Ó °³¼±µÇ¾î Á¤È®¼ºÀ» À¯ÁöÇϸ鼭 ºÒÇÊ¿äÇÑ Ä§½ÀÀû Áø´ÜÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿¸¦ ±â¹ÝÀ¸·Î ÇÏ´Â ½ºÄھ µµ±¸´Â ¸®½ºÅ© °èÃþÈ­ ¹× Ãß°¡ °Ë»ç¸¦ À§ÇÑ È¯ÀÚ ¼±ÅÃÀ» °³¼±Çϰí Ä¡·á °æ·Î¸¦ ÃÖÀûÈ­ÇÕ´Ï´Ù.

¿ëµµº°·Î´Â ½ºÅ©¸®´×°ú Á¶±â ¹ß°ßÀÇ ºÐ¾ß°¡ 2024³â ½ÃÀå¿¡¼­ °¡Àå ³ôÀº Á¡À¯À² 40.2%¸¦ Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â °øÁß º¸°Ç ½Ã½ºÅÛ°ú °³ÀÎÀÇ ÀÓ»ó Áø·á ¸ðµÎ¿¡¼­ Á¶±â Áø´ÜÀÌ Áß¿äÇØÁ³±â ¶§¹®ÀÔ´Ï´Ù. ½ºÅ©¸®´× Ç÷§ÆûÀº ÇöÀç ´ë·®ÀÇ ¿öÅ©Ç÷ο츦 À§ÇØ ¼³°èµÇ¾úÀ¸¸ç, Ç÷¾× ¶Ç´Â ¼Òº¯À» ±â¹ÝÀ¸·Î ÇÏ´Â ¹ÙÀÌ¿À¸¶Ä¿ ÃøÁ¤À» Ȱ¿ëÇÏ¿© ÃÖ¼ÒÇÑÀÇ Ã³¸®·Î ºü¸£°í ¾ÈÁ¤ÀûÀÎ °á°ú¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¼Ö·ç¼ÇÀº ÀÏ»óÀûÀÎ °Ç°­ Áø´Ü¿¡ ¸Å¿ì ÀûÇÕÇÏ¸ç ½Å¼ÓÇÑ ³³±â¿Í »ç¿ë ÆíÀǼºÀÌ Áß¿äÇÑ ¿Ü·¡ ȯ°æ¿¡¼­ ºü¸£°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ºñħ½ÀÀû °Ë»çÀÇ Æí¸®¼º°ú ÀÌ¿ëÀÇ ¿ëÀ̼ºÀº Àü ¼¼°èÀûÀ¸·Î Àü¸³¼±¾Ï ¿¹¹æÀü·«¿¡ ÇʼöÀûÀÔ´Ï´Ù.

ºÏ¹Ì Àü¸³¼±¾Ï ¹ÙÀÌ¿À¸¶Ä¿ 2024³â Á¡À¯À²Àº 42.5% ÀÌ Áö¿ªÀº ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº ÀÌȯÀ², ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΠȹµæ °¡¼ÓÈ­ µîÀÇ ÀÌÁ¡À» ´©¸®°í ÀÖ½À´Ï´Ù. ¹Ì±¹°ú ij³ª´Ù´Â ¿Õ¼ºÇÑ °Ç°­ °ü¸® ÁöÃâ°ú °è¸ù Ȱµ¿ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÃÖ÷´Ü Áø´Ü Ç÷§ÆûÀÇ µµÀÔÀ¸·Î °è¼Ó ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ, Á¤ºñµÈ Áø´Ü¿ë ¿¡ÄڽýºÅÛ, ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ Á¸Àç°¡ ÀÌ Áö¿ªÀÇ Çõ½ÅÀ» ´õ¿í °­È­Çϰí ÀÖ½À´Ï´Ù. ½Å·Ú¼ºÀÌ ³ô°í ½Å¼ÓÇϸç ħ½ÀÀÌ ÀûÀº ¾Ï Áø´ÜÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁü¿¡ µû¶ó ÀÌ ÁÖµµÀû ÁöÀ§´Â Áö¼ÓµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Myriad Genetics, QIAGEN, Siemens, Veracyte, Genomic Health, F. Hoffmann-La Roche, MDxHealth, Thermo Fisher Scientific, Merck KGaA¿Í °°Àº °æÀï ±¸µµ¸¦ À籸¼ºÇÏ´Â ÁÖ¿ä ±â¾÷ÀÌ ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº ¿¬±¸°³¹ß ÅõÀÚ¸¦ ÅëÇØ °Ë»ç Æ÷Æ®Æú¸®¿À¸¦ È®´ëÇϰí Á¾¾çÇÐ ¿¬±¸¼Ò, Çмú±â°ü, º´¿ø°úÀÇ Á¦ÈÞ¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ Ç÷§ÆûÀÇ °¨µµ¿Í ƯÀ̼ºÀ» Çâ»ó½Ã۱â À§ÇØ ±â¾÷Àº ÷´Ü À¯Àüü ¹× ´Ü¹éÁúüÇÐ ±â¼úÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼¼°è ÆÇ¸Å, Á¦Á¶ ±Ô¸ð È®´ë, ½ÃÀå ÅõÀÔ±îÁöÀÇ ½Ã°£À» ´ÜÃàÇϱâ À§ÇÑ ¾à»ç ½ÂÀÎ ÃëµæÀ» À§ÇÑ Àü·«Àû Á¦ÈÞµµ ÁøÇàÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº ±â¾÷µéÀÌ µ¿¹ÝÁø´ÜÁ¦ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, À̰ÍÀº Á¤¹ÐÀÇ·á¿¡ Á÷Á¢ ¿¬°áµÇ¾î ÀÖÀ¸¸ç, Ä¡·á Á¶Á¤°ú ȯÀÚ °á°ú¸¦ Çâ»ó½ÃŰ´Â °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : À¯Çüº°, 2021-2034³â

Á¦6Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¿ëµµº°, 2021-2034³â

Á¦7Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2034³â

Á¦8Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Áö¿ªº°, 2021-2034³â

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Prostate Cancer Biomarkers Market was valued at USD 4.7 billion in 2024 and is estimated to grow at a CAGR of 13.5% to reach USD 16.5 billion by 2034. The market growth is propelled by the rising number of prostate cancer cases, particularly in aging male populations, and the evolution of advanced diagnostics. Growing awareness of early screening, along with a rise in government-sponsored healthcare programs, is fueling adoption across primary care settings. The integration of next-generation diagnostics, such as artificial intelligence-driven assessments, liquid biopsies, and genomic analysis platforms, is enhancing early-stage detection while supporting personalized therapeutic decisions. Emerging economies are also increasing investments in health infrastructure, which is broadening access to precision-based testing methods. These biomarker-driven strategies are reshaping cancer care by offering better accuracy, reduced invasiveness, and faster diagnostic workflows.

Prostate Cancer Biomarkers Market - IMG1

Major industry contributors such as OPKO Health, Beckman Coulter, Bio-Rad Laboratories, and Bio-Techne are at the forefront of driving innovation in the prostate cancer biomarkers market. These companies are not only enhancing the accuracy and speed of detection through cutting-edge diagnostic platforms but also shaping the future of personalized cancer care. By developing non-invasive, highly sensitive biomarker assays and integrating them with AI-based diagnostic systems, they enable earlier identification of disease, better monitoring of progression, and more effective treatment planning.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$4.7 Billion
Forecast Value$16.5 Billion
CAGR13.5%

The protein biomarkers segment generated USD 2.4 billion in 2024 and is forecasted to reach USD 8.2 billion by 2034, growing at a CAGR of 13.1%. Their dominance is anchored in widespread clinical acceptance and their routine use for disease detection and progression tracking. Biomarkers in this category, which are easily measured through standard blood assays, remain the first-line diagnostic tools due to their proven reliability, cost-effectiveness, and strong correlation with prostate cancer risk. Ongoing research continues to refine these biomarker technologies, allowing them to reduce unnecessary invasive diagnostics while maintaining accuracy. New biomarker-based scoring tools are also improving risk stratification and patient selection for further testing, optimizing treatment pathways.

In terms of application, the screening and early detection segment held the highest share of the market in 2024, accounting for 40.2%. This is attributed to the growing emphasis on early diagnosis in both public health systems and individual clinical practices. Screening platforms are now designed for high-volume workflows and utilize blood or urine-based biomarker assays to deliver fast, reliable results with minimal processing. These solutions are highly suitable for routine health checks and are expanding rapidly in outpatient environments where fast turnaround and ease of use are critical. The convenience and accessibility of non-invasive tests are making them integral to prostate cancer prevention strategies globally.

North America Prostate Cancer Biomarkers Market held 42.5% share in 2024. The region benefits from advanced medical infrastructure, high rates of disease incidence, and accelerated pathways for regulatory approvals. The US and Canada continue to lead in adopting cutting-edge diagnostic platforms, driven by strong healthcare expenditure and rising public awareness campaigns. Continuous investment in research, a well-developed diagnostics ecosystem, and the presence of major market participants further support innovation in this region. This leadership position is expected to persist as demand grows for reliable, fast, and minimally invasive cancer diagnostics.

Companies such as Myriad Genetics, QIAGEN, Siemens, Veracyte, Genomic Health, F. Hoffmann-La Roche, MDxHealth, Thermo Fisher Scientific, and Merck KGaA are among the key players reshaping the competitive landscape. These include expanding their test portfolios through R&D investments and strengthening partnerships with oncology labs, academic institutions, and hospitals. Firms are leveraging advanced genomic and proteomic technologies to improve the sensitivity and specificity of their biomarker platforms. They're also entering strategic collaborations for global distribution, scaling up manufacturing, and securing regulatory approvals to speed up time-to-market. Many companies are focusing on companion diagnostics development, which ties directly into precision medicine, enhancing treatment alignment and patient outcomes.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â